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Abstract
Background: People rapidly ascending to high altitudes (>2500 m) may suffer from acute mountain sickness (AMS).
The association between smoking and AMS risk remains unclear. Therefore, we performed a meta-analysis to
evaluate the association between smoking and AMS risk.
Methods: The association between smoking and AMS risk was determined according to predefined criteria
established by our team. Meta-analysis was conducted according to the PRISMA guidelines. We included all
relevant studies listed in the PubMed and Embase databases as of September 2015 in this meta-analysis and
performed systemic searches using the terms “smoking”, “acute mountain sickness” and “risk factor”. The included
studies were required to provide clear explanations regarding their definitions of smoking, the final altitudes
reached by their participants and the diagnostic criteria used to diagnose AMS. Odds ratios (ORs) were used to
evaluate the association between smoking and AMS risk across the studies, and the Q statistic was used to test OR
heterogeneity, which was considered significant when P < 0.05. We also computed 95% confidence intervals (CIs).
Data extracted from the articles were analyzed with Review Manager 5.3 (Cochrane Collaboration, Oxford, UK).
Results: We used seven case-control studies including 694 smoking patients and 1986 non-smoking controls to
analyze the association between smoking and AMS risk. We observed a significant association between AMS and
smoking (OR = 0.71, 95% CI 0.52–0.96, P = 0.03).
Conclusions: We determined that smoking may protect against AMS development. However, we do not advise
smoking to prevent AMS. More studies are necessary to confirm the role of smoking in AMS risk.
Keywords: Smoking, Acute mountain sickness, Association, High altitude, Meta-analysis, Risk factor
Background
People rapidly ascending to high altitudes (>2500 m) may
suffer from acute mountain sickness (AMS), an illness char-
acterized by symptoms such as headache, loss of appetite,
nausea and vomiting, dizziness, fatigue and sleep distur-
bances [1, 2]. Not all symptoms must be present for an
AMS diagnosis. In some severe cases, AMS may evolve into
high-altitude cerebral edema (HACE) or high-altitude pul-
monary edema (HAPE), conditions that may threaten pa-
tient health and well-being [3]. AMS symptoms usually
occur during the first night at high altitude. AMS remission
typically occurs a few days later, once affected individuals
have adapted to the new altitude [4]. The Lake Louise
Scoring System is a standard commonly used for diagnos-
ing AMS that was established at the 1991 International
Hypoxia Symposium [5, 6]. Other standards, including the
Environmental Symptom Questionnaire (ESQ), the AMS
Symptom Questionnaire, and the General High-Altitude
Questionnaire, have also been used [7].
Despite decades of research, the pathophysiological
mechanisms underlying AMS development remain poorly
understood. Previous studies have attempted to identify risk
factors that can be used to predict AMS susceptibility. A
substantial number of studies have shown that age [8, 9],
body mass index (BMI) [9, 10], arterial oxygen saturation
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[11], sleep quality [12] and gender [13, 14] are correlated
with AMS susceptibility. However, other studies have found
that these factors do not play a role in AMS development
[15]. MacInnis et al. [16] reviewed the relationships be-
tween various genetic factors and AMS in 2010 and found
no genetic factors that can reliably predict AMS. Therefore,
searching for factors that are related to AMS development
remains necessary. Wu et al. [17] reported that the inci-
dence of AMS was lower among smokers than among
non-smokers and that smokers exhibited lower AMS scores
than non-smokers. A similar conclusion was reached by
Song et al. [18]. In addition to the above-mentioned re-
ports, other studies suggest that smoking is a protective fac-
tor for AMS. For example, You et al. [19] found that the
incidence of AMS among smokers (26.1%) was significantly
lower than that among non-smokers (47.2%). However,
studies conducted by Ziaee et al. [15], Gaillard et al. [20]
and Vinnikov et al. [21] suggested that there was no signifi-
cant correlation between AMS and smoking habits.
Recently, Vinnikov et al. [22] performed a meta-analysis
showing that smoking was not significantly associated with
AMS. Different detailed method might get different conclu-
sions. Based on multiple reviews of several articles, we de-
termined that some studies did not use common standards
for diagnosing AMS and that other studies did not provide
concrete data regarding the incidence of AMS among
smokers and non-smokers. Additionally, several studies
used non-rigorous inclusion criteria, which likely influenced
their results; thus, we used strict inclusion and exclusion
criteria in this analysis, which we performed with the aim
of investigating the association between smoking and AMS
risk to add to the knowledge base regarding this issue.
Methods
Search strategy
The PRISMA guidelines were used to screen eligible
studies. We searched the English-language literature re-
garding smoking and AMS that was published before
September 2015 using the PubMed and Embase data-
bases. Our search strategy included the following key
words: 1) acute mountain sickness (AMS), 2) smoking
and 3) risk factor. We did not include abstracts or un-
published reports in the analysis. If the same subjects
were published in different publications, the study with
the more comprehensive analysis was extracted. Two in-
vestigators extracted the data independently; in the event
of disagreement, consensus was reached via discussion.
Inclusion and exclusion criteria
The following studies were included in the analysis: 1) in-
cluding smoking and non-smoking data, 2) regarding AMS,
3) providing original data regarding the numbers of
smokers and non-smokers and AMS occurrence, 4) using
high-altitude exposure definitions similar to those of other
studies, 5) original data were obtained at an altitude above
3000 m, and 6) using clear and common diagnostic criteria
for AMS.
The following studies were excluded: 1) lacking specific
data regarding smoking and non-smoking, 2) studies with
insufficient information about the number of AMS cases,
3) studies that did not mention the direct relationship be-
tween smoking and AMS, and 4) studies that did not use
or discuss common diagnostic criteria for AMS.
Data extraction and synthesis
For each study, the first author, year of publication, alti-
tude, and numbers of smokers and non-smokers with
AMS were recorded. If one study provided multiple
detailed data sets related to smoking and AMS, all of
these data were recorded.
Statistical analysis
The association between smoking and AMS was
assessed in this meta-analysis. To determine the associ-
ation between smoking and AMS, we performed a
comparison of the prevalences of AMS in smokers and
non-smokers. Odds ratios (ORs) were used to evaluate
the association between smoking and AMS risk across
the studies. The Q statistic was used to test OR hetero-
geneity, which was considered significant when P < 0.05.
The I2 statistic was also calculated to quantitatively as-
sess inconsistency. We also computed 95% confidence
intervals (CIs). Additionally, if there was significant het-
erogeneity, we used a random effects model to analyze
the study. If there was no heterogeneity, we used a fixed
effects model [2, 23–25]. We also performed Begg’s and
Egger’s tests when significant differences (P < 0.05) were
present to determine if publication bias was also present.
Results
Description of studies
We initially retrieved 25 articles from PubMed and
Embase. Based on the above-mentioned pre-specified
exclusion criteria, we re-evaluated all of the studies. We
found that 15 articles lacked concrete data pertaining to
smoking and non-smoking groups, 2 articles lacked
Fig. 1 Selection flow chart
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Table 1 Extracted data characteristics
Research Altitude
(m)
Sample size AMS Normal Diagnosis of AMS
with cut-off value
Age (mean) BMI (mean) Sex (m/f)
Smoking Non-smoking Smoking Non-smoking Smoking Non-smoking AMS Normal AMS Normal AMS Normal
Ren, 2015 [14] 4300 16 64 3 32 13 32 LLS > 3 38.1 38.6 24.7 26.2 9/26 22/23
Wu, 2012 [17] 4525 182 200 71 102 111 98 LLS >3 OR LLS >4
You, 2012 [19] 4300 138 176 36 83 102 93 LLS > 4 20.08 20.25 21.31 21.47 119/0 195/0
MacInnis, 2013 [26] 4380 147 344 42 125 105 219 LLS ≥ 3 100/67 244/80
Mairer, 2010(a) [28] 3454 9 66 4 26 5 40 LLS ≥ 4 35.1 34.5 23.4 23.3 25/5 39/6
Mairer, 2010(b) [28] 3817 13 67 3 25 10 42 36.2 38.1 23.5 22.8 22/6 41/11
Mairer, 2009 [27] 3500 61 370 12 58 49 312 LLS ≥ 4 38.4 37.2 23.7 23.3 50/20 266/86
Schneider, 2002(a) [4] 4559 56 331 16 103 40 228 ESQ ≥ 0.70 38.2 22.6 314/73
Schneider, 2002(b) [4] 4559 72 368 21 99 51 269 37.0 22.7 359/81
Mairer (2010) [28] reported two studies (2010a and 2010b) that were independent. Schneider (2002) [4] also published two studies (2002a and 2002b) that were independent. Schneider (2002) [4] used the
Environmental Symptom Questionnaire (ESQ) to diagnose AMS using an ESQ cut-off value of 0.70, which corresponded to a Lake Louise Score (LLS) of 4. Wu (2012) [17] did not provide original data regarding age,
gender or BMI. MacInnis (2013) [26] did not provide clear data regarding age or BMI. Schneider (2002) [4] provided only data regarding the total population of subjects. In addition, we analyzed how the studies












AMS diagnostic criteria, 1 article did not provide the
original data. Seven articles were ultimately included ac-
cording to our exclusion and inclusion criteria (Fig. 1).
The studies by Schneider et al. [4] and Mairer et al. [28]
each provided two data sets; the subjects in the two
groups were not repeat subjects, so we considered the
studies in question to be independent studies, which
were identified using the indicated key words. The fol-
lowing search terms were used: (acute mountain sickness
or AMS or high altitude) and (smoking) and (risk factor).
We included a total of seven articles including 694 smok-
ing subjects and 1986 non-smoking controls in our meta-
analysis. One report used the Environmental Symptom
Questionnaire (ESQ), while the other reports used the
Lake Louise Scoring (LLS) System. The extracted data are
presented in Table 1.
Meta-analysis results
Seven articles [4, 14, 17, 19, 26–28] including 694
smokers and 1986 non-smoking controls were included
in our study. We analyzed these 7 articles and found
that smoking could reduce the prevalence of AMS. This
allowed us to use RevMan 5.0 to analyze the data. Het-
erogeneity analysis showed that df = 8, P = 0.05, and I2 =
49% (Fig. 2), indicating that the 7 articles were not
homogeneous in nature. Smoking could reduce the
prevalence of AMS, with an OR of 0.71 (95% CI 0.52–
0.96). The test for overall effect, Z = 2.19 (P = 0.03),
clearly showed that smoking was lower in the AMS
group than in the control group; this difference was sta-
tistically significant.
Publication bias analysis
We constructed a funnel plot to determine if publication
bias was present. Based on the symmetry of the funnel
plot, as shown in Fig. 3, we postulate that no publication
bias was present in the articles included in our analysis.
Discussion
In our study, we analyzed a total of 694 smokers and
1986 non-smoking controls from seven published arti-
cles. To our knowledge, prior our study, only one meta-
analysis explored the association between smoking and
AMS and found that smoking was not significantly asso-
ciated with AMS [22]. Different selection criteria may
lead to different results; we used strict inclusion and ex-
clusion criteria and obtained results that contrasted with
those of the previous study.
Our meta-analysis results contrast with the traditional
opinion that smokers are more like to develop AMS than
non-smokers. The following study findings may explain
why smoking protects people from AMS. First, Sanchez
del Rio et al. [29] found that nitric oxide (NO) can irritate
and discharge the nerve fibers constituting the trigemino-
vascular system, resulting in high-altitude headaches.
Moreover, NO increases blood-brain barrier permeability,
which may also cause headaches [30]. Studies have shown
that endothelial function can be impaired by small
amounts of oxygen free radicals in smokers, resulting in
decreased NO synthesis and increased NO decomposition
Fig. 2 Forest plot of the relationship between AMS and smoking. The disease occurrence (odds ratio) summary is displayed in the comparison
between smokers and non-smokers, and 95% confidence intervals are shown on the extreme left and right. The incidence of AMS is expressed as
the number of events
Fig. 3 Funnel plot of publication bias. According to the funnel plot,
no publication bias was present. Each point represents a separate
report providing information regarding the indicated association
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[31]. Therefore, lower brain NO levels may, to a certain
extent, protect smokers from developing headaches [17].
Second, periodic breathing, a breathing pattern character-
ized by waxing and waning respiration, may play a major
role in sleep disturbances at high altitude [32]. Studies
have shown that breathing regulation may be influenced
by NO and carbon monoxide (CO) [33, 34]. Because of
higher CO and NO levels, smokers experience fewer sud-
den bursts of breathing and subsequent arousals from
sleep [32]. Therefore, smokers usually exhibit more stable
breathing and sleep better than non-smokers [17]. Third,
previous experiments have demonstrated that CO can
simultaneously increase vascular smooth muscle apoptosis
and decrease vascular smooth muscle cell proliferation,
which is thought to be beneficial with respect to pulmon-
ary arterial pressure (PAP) [35]. Reports have also shown
that CO reverses established pulmonary arterial hyperten-
sion (PAH). Thus, PAP can be decreased by increases in
CO inhalation, which protect against the development of
hypoxia. Therefore, higher CO levels in smokers prevent
the development of vascular disorders and may thus de-
crease the risk of AMS. Fourth, smokers exhale more CO,
which can bind to hemoglobin (Hb) and reduce its oxygen
carrying potential [36]. In contrast, You et al. [19] re-
ported that smokers exhale more CO, but the occurrence
of AMS was lower in non-smokers than in smokers;
therefore, the fraction of exhaled CO may protect against
AMS within a particular range. Fifth, Baumgartner et al.
[37] reported that AMS was related to cerebral blood flow.
Another study reported that the cerebral blood flow
velocities of smokers were lower than those of non-
smokers [18], resulting in a lower incidence of headaches
and a lower incidence of AMS. Finally, the present study
clearly determined that cigarette smoking is one of the
major causes of polycythemia [38]. Moderate increases in
Hb levels have been shown to be beneficial with respect to
blood oxygen-carrying capacity at high altitude in
smokers, as these increases may correct reductions in ar-
terial oxygen saturation, which have been shown to be
closely associated with AMS [39].
While smoking appears decrease the risk of AMS de-
velopment, we do not advise smoking to prevent AMS.
Smoking cigarettes increases the risk of developing car-
diorespiratory diseases, as well as other diseases, includ-
ing cancer [17]. However, further research regarding the
mechanisms underlying this phenomenon may enable us
to identify other preventive measures that have the same
beneficial effects as smoking. In any event, the best way
to prevent AMS is by making a gradual ascent and
allowing sufficient time for acclimatization to higher alti-
tudes [32].
There were several limitations to our study. First, only
a relatively small number of studies were eligible for in-
clusion in our analysis, which may have limited our
results. Second, five studies did not attempt to docu-
ment CO/NO levels. Third, patients were diagnosed
with AMS by different observers, which might have in-
fluenced the outcomes of the studies. Fourth, we did not
analyze other factors associated with AMS, such as age,
gender, and BMI.
Conclusion
We conclude that smoking may protect against AMS.
However, more case-control studies are necessary to
clarify the role of smoking in AMS risk further.
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